Logo wahanariau.com
  2. Zymeworks

Zymeworks

Index
Globenewswire

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

Senin, 26 Oktober 2026 - 22:09:08 Wib
Globenewswire

Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma

Senin, 19 Oktober 2026 - 22:46:32 Wib
Globenewswire

Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results

Kamis, 15 Oktober 2026 - 23:13:13 Wib
Globenewswire

Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition

Senin, 28 September 2026 - 21:58:46 Wib
Globenewswire

Zymeworks Completes Acquisition of Theravance Biopharma

Kamis, 24 September 2026 - 22:16:40 Wib
Globenewswire

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

Selasa, 25 Agustus 2026 - 22:25:18 Wib
Globenewswire

Zymeworks Announces Participation in Upcoming Investor Conferences'

Selasa, 11 Agustus 2026 - 21:19:19 Wib
Globenewswire

Zymeworks to Acquire Theravance Biopharma, Inc.

Senin, 29 Juni 2026 - 22:28:57 Wib
Globenewswire

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

Senin, 15 Juni 2026 - 20:57:09 Wib
Globenewswire

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

Jumat, 15 Mei 2026 - 21:46:18 Wib
Globenewswire

Zymeworks Announces Participation in Upcoming Investor Conferences`

Rabu, 13 Mei 2026 - 22:17:25 Wib
Globenewswire

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

Rabu, 22 April 2026 - 21:15:47 Wib
Globenewswire

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Sabtu, 18 April 2026 - 22:44:05 Wib
Globenewswire

Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

Kamis, 09 April 2026 - 20:35:15 Wib
Globenewswire

Zymeworks Appoints Kristin Stafford as Chief Financial Officer

Rabu, 01 April 2026 - 22:43:21 Wib
Globenewswire

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate

Senin, 30 Maret 2026 - 22:23:01 Wib
Globenewswire

Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

Kamis, 19 Maret 2026 - 04:10:33 Wib
Globenewswire

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

Rabu, 18 Maret 2026 - 04:56:51 Wib
Globenewswire

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

Selasa, 03 Maret 2026 - 05:01:21 Wib
Globenewswire

Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

Selasa, 13 Januari 2026 - 05:55:47 Wib
Globenewswire

Zymeworks Outlines Strategic Priorities and Outlook for 2026

Selasa, 13 Januari 2026 - 05:52:01 Wib
Globenewswire

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

Rabu, 07 Januari 2026 - 06:05:03 Wib
Globenewswire

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

Rabu, 19 November 2025 - 03:43:44 Wib
Globenewswire

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

Rabu, 19 November 2025 - 03:42:51 Wib
Globenewswire

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Senin, 17 November 2025 - 19:50:43 Wib